Neoadjuvant systemic therapy (NST) that contains trastuzumab in addition to neoadjuvant chemotherapy leads to high pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer (IBC) [1–3]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.